Understanding how the body breaks down IgE antibodies involved in allergies
Official title: Elucidating the Cellular and Molecular Mechanisms of IgE Catabolism
Funded at Yale University · NIH-11076185 · Data updated 2026-11-12
This study is looking at how the body breaks down IgE antibodies, which are responsible for allergies, to help find new ways to treat allergies and improve options for people who suffer from them.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $48,974 |
| NIH project number | 5F31AI183702-02 |
| Project ID | NIH-11076185 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from food or airway allergies, particularly those with persistent IgE-mediated allergic responses.
✕Less likely to help
Patients without IgE-mediated allergies or those who do not experience allergic reactions may not benefit from this research.
What this research studies
This research investigates the biological processes that control the breakdown of IgE antibodies, which are crucial in causing allergic reactions. By studying how IgE interacts with immune cells like mast cells and basophils, the research aims to uncover the mechanisms that differentiate IgE from other antibodies. The project utilizes transgenic mice to explore these processes, potentially leading to new treatments for allergies by targeting IgE specifically. Patients may benefit from a better understanding of their allergies and improved therapeutic options.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for allergies, potentially reducing symptoms and improving quality of life for patients.
How similar studies have gone: While the specific mechanisms of IgE catabolism are less explored, similar research on antibody regulation has shown promise in improving treatments for other conditions.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Zhou, Kenneth — Yale University
- Study coordinator: Zhou, Kenneth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.